Vir Biotechnology

New Capabilities

Sponsor of ECLIPSE 1; planning an FDA submission in mid-2027

Hepatitis D only infects people who already have hepatitis B, and it is the more aggressive of the two. Until this year, the United States had no approved drug for it. On November 8, Vir Biotechnology reported that a two-drug combination cleared detectable virus and normalized levels of alanine aminotransferase, a liver enzyme, in 44% of patients after 48 weeks.

Updated Yesterday